Syngene International Limited — Board Meeting, 23-07-2025: Outcome of Board Meeting

Syngene International's Board approved the financial results for the quarter ended June 30, 2025. The company posted consolidated revenue from operations of ₹874.5 Cr, up from ₹789.7 Cr year-on-year. Net profit stood at ₹86.7 Cr, compared to ₹75.7 Cr in the same quarter last year. Basic Earnings Per Share (EPS) for the quarter was ₹2.16. Key strategic updates for the period include the acquisition of a US biologics site, expanding bioreactor capacity, and securing a new license for its Bangalore biologics manufacturing facility, enhancing global service offerings.